Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Prognostic significance of tumor infiltrating lymphocytes on first-line pembrolizumab efficacy in advanced non-small cell lung cancer
Kyoichi Kaira, Ou Yamaguchi, Tomonori Kawasaki, et al.
Discover Oncology (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 18

Showing 18 citing articles:

Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach
Miguel López de Rodas, María Villalba, Miguel F. Sanmamed, et al.
Nature Reviews Clinical Oncology (2025)
Closed Access | Times Cited: 2
Progresses in biomarkers for cancer immunotherapy
Xuwen Lin, Chenyu Zong, Zhihan Zhang, et al.
MedComm (2023) Vol. 4, Iss. 5
Open Access | Times Cited: 18
Clinical impact of inflammatory and nutrition index based on metabolic tumor activity in non‑small cell lung cancer treated with immunotherapy
Koki Ito, Kousuke Hashimoto, Kyoichi Kaira, et al.
Oncology Letters (2024) Vol. 27, Iss. 3
Open Access | Times Cited: 3
Patient-derived tumoroids and proteomic signatures: tools for early drug discovery
Hélène Lê, Jules Deforges, Pasquale Cutolo, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Engineering PD-1-targeted small protein variants for in vitro diagnostics and in vivo PET imaging
Joanna Maria Mierzwicka, Hana Petroková, Leona Rašková Kafková, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 2
Potential predictors of the pathologic response after neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer: a narrative review
Kyoichi Kaira, Yoshinobu Ichiki, Hisao Imai, et al.
Translational Lung Cancer Research (2024) Vol. 13, Iss. 5, pp. 1137-1149
Open Access | Times Cited: 2
Peripheral CD4 memory T cells predict the efficacy of immune checkpoint inhibitor therapy in patients with non-small cell lung cancer
Minehiko Inomata, Masahiro Matsumoto, Naoki Takata, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 5
Tumor Characteristics and Treatment Responsiveness in Pembrolizumab-Treated Non-Small Cell Lung Carcinoma
Haiyan Li, Sunitha Shyam Sunder, Karan Jatwani, et al.
Cancers (2024) Vol. 16, Iss. 4, pp. 744-744
Open Access | Times Cited: 1
PD-L1 Expression and Tumour Microenvironment Patterns in Resected Non-Small-Cell Lung Cancer
Giedrė Gurevičienė, Jurgita Matulionė, Lina Poškienė, et al.
Medicina (2024) Vol. 60, Iss. 3, pp. 482-482
Open Access | Times Cited: 1
Establishment of an ovarian cancer exhausted CD8+T cells-related genes model by integrated analysis of scRNA-seq and bulk RNA-seq
Tian Hua, Deng-xiang Liu, Xiao-chong Zhang, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 1
Association between pretreatment C-reactive protein level and survival in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis
Haoyu Wang, Ruiyuan Yang, Ke Zhou, et al.
International Immunopharmacology (2023) Vol. 124, pp. 110937-110937
Closed Access | Times Cited: 4
Association between CD8+ tumor-infiltrating lymphocytes and prognosis of non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis
Qi-Ming Zheng, Yuanyuan Li, Ye-Peng Wang, et al.
Expert Review of Anticancer Therapy (2023) Vol. 23, Iss. 6, pp. 643-659
Closed Access | Times Cited: 3
Extended ICI treatment after first‐line chemoimmunotherapy could predict the clinical benefit of ramucirumab plus docetaxel in advanced non‐small lung cancer: Post hoc analysis from NEJ051 (REACTIVE study)
Ou Yamaguchi, Keita Mori, Saori Takata, et al.
Thoracic Cancer (2023) Vol. 15, Iss. 2, pp. 163-171
Open Access | Times Cited: 2
Prognostic significance of peripheral and tumor-infiltrating lymphocytes in newly diagnosed stage III/IV non-small-cell lung cancer
Fenge Li, Chong Tian, Yupeng Wang, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access
Prognostic significance of LAT1 expression in pleural mesothelioma
Ryo Taguchi, Kyoichi Kaira, Yu Miura, et al.
Heliyon (2024) Vol. 10, Iss. 17, pp. e37414-e37414
Open Access
Prognostic implications of tumor-infiltrating lymphocytes in non-small cell lung cancer: a systematic review and meta-analysis
Yan Qin, Shuai Cheng Li, Lang He, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Peripheral Circulating Blood Cells Deviation Based on Tumor Inflammatory Microenvironment Activity in Resected Upstaged Lung Adenocarcinomas
Alessandro Bonis, Francesca Lunardi, Giulia Pagliarini, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 24, pp. 7597-7597
Open Access
Interstitial lung diseases with concomitant lung cancer: a data mining approach revealing a complex condition with gender- and immune-associated specific implications
Fabio Massimo Perrotta, Donato Lacedonia, Vito D’Agnano, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
Page 1

Scroll to top